Moreover, pharmacological administration of recombinant FGF21 reduced serum triglyceride (TG) and low-density lipoprotein cholesterol (LDL) while increased high-density lipoprotein cholesterol (HDL) levels, and it reversed steatosis in mouse models of obesity and diabetes (14, 17, 24). Here, FGF21 is linked to obesity due to melanocortin 4 receptor deficiency.